# EDGAR Filing Document

**Accession Number:** 0001769759
**File Stem:** 0001104659-25-071470
**Filing Date:** 2025-7
**Character Count:** 14502
**Document Hash:** b5d4975c91502de68277604c04a00a1c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-071470.hdr.sgml**: 20250729

**ACCESSION NUMBER**: 0001104659-25-071470

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250726

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250729

**DATE AS OF CHANGE**: 20250729

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Monogram Technologies Inc.
- **CENTRAL INDEX KEY:** 0001769759
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 812349540
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41707
- **FILM NUMBER:** 251158012

**BUSINESS ADDRESS:**
- **STREET 1:** 53 BRIDGE STREET UNIT 507
- **CITY:** BROOKLYN
- **STATE:** NY
- **ZIP:** 11201
- **BUSINESS PHONE:** (718) 576-3205

**MAIL ADDRESS:**
- **STREET 1:** 3913 TODD LANE
- **STREET 2:** SUITE 307
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78744

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MONOGRAM ORTHOPAEDICS INC
- **DATE OF NAME CHANGE:** 20190305

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): July 26, 2025**

**Monogram Technologies Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41707** | **81-3777260** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**3919 Todd Lane, Austin, TX 78744**

**(Address of principal executive offices, including zip code)**

**Registrant's telephone number, including area code: (512) 399-2656**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading <br> Symbol(s)** | **Name of each exchange<br> on which registered** |
| **Common Stock, par value $0.001 per share** | **MGRM** | **The Nasdaq Stock Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **ITEM 7.01** | **REGULATION FD DISCLOSURE** |

---

On July 29, 2025, Monogram Technologies Inc. (the "Company") issued a press release (the "Press Release") announcing that the Company performed the world's first fully autonomous saw-based robotic knee replacement surgery. The procedure utilized the Company's mBôs™ TKA System and was performed at the Krishna Shalby Hospital in Ahmedabad India.

The foregoing disclosure is qualified in its entirety by the full text of the Press Release.

A copy of the Press Release is attached as Exhibit 99.1, and is hereby incorporated by reference into this Item 7.01. The information contained in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed "filed" for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, except to the extent expressly stated in such filing.

**Cautionary Note Regarding Forward-Looking Statements**

This Current Report on Form 8-K, including the Press Release, contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in the Company's lack of profitability and need for additional capital to grow its business; the Company's dependence on partners to further the development of its product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections of the Company's latest annual and quarterly reports and other filings with the SEC.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. The Company undertakes no obligation to revise or update any forward-looking statements made in this Current Report on Form 8-K to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

---

| | |
|:---|:---|
| **ITEM 9.01** | **FINANCIAL STATEMENTS AND EXHIBITS** |

---

**(d)** **Exhibits:** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](tm2521919d1_ex99-1.htm) | [Press Release dated July 29, 2025](tm2521919d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | **MONOGRAM TECHNOLOGIES INC.** |
| Dated: July 29, 2025 | /s/ Benjamin Sexson |
|  | Benjamin Sexson |
|  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm2521919d1_ex99-1img001.jpg)

**Monogram Technologies Announces World's First Fully Autonomous Saw-Based Robotic Knee Replacement Surgery**

*The Procedure Utilized Monogram's mBôs TKA System Performed in India with Shalby Hospitals*

*Groundbreaking Procedure Delivers the World's First Autonomous Saw-Based Robotic TKA Surgery on a Live Patient*

**AUSTIN, TX – July 29, 2025 –** Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced that on Saturday, July 26, 2025, Monogram completed the first ever fully autonomous saw-based robotic knee replacement procedure on a live patient.

The procedure was performed at the Krishna Shalby Hospital in Ahmedabad India, as part of Monogram's multi-center clinical trial in India for the Monogram TKA System.

As <u>previously announced</u>, Monogram and Shalby partnered to evaluate the safety and effectiveness of the mBôs TKA System with the Consensus CKS implant, which is substantially equivalent to the Monogram mPress implants for regulatory purposes. On April 29, 2025, Monogram obtained regulatory approval from India's Central Drugs Standard Control Organization ("CDSCO") to import its mBôs TKA system to conduct a multi-center clinical investigation evaluating the safety and effectiveness of the Monogram TKA System. The clinical trial includes 102 total knee replacement procedures, with a three-month clinical follow-up, conducted across multiple sites in India.

"The first fully autonomous knee replacement on a live patient using Monogram's TKA System is a tremendous milestone for the Company. The procedure marks the culmination of years of hard work and dedication by our incredible team. I feel honored and proud to work with such incredible and dedicated individuals at Monogram. The system appears to have flawlessly executed the plan based on intraoperative surgeon evaluation, including intraoperative laxity estimation and achievement of planned alignment. I believe Monogram's product will have a significant positive impact on the standard of care for orthopedic medicine in the years to come," said Benjamin Sexson, CEO of Monogram Technologies.

"Watching the ease with which the system cut and executed the procedure was incredibly fulfilling. The safety and accuracy of the system were on obvious display. It really was an amazing moment watching Dr. Patil realize that robots can be more than marketing gimmicks but tools that actually change how knee replacements can be done better, said founder Dr. Douglas Unis. "Based on years of evaluating technology, watching this surgery was the final validation I needed to know with certainty that we have a groundbreaking product. It was incredible that there was so little stress, given the level of autonomy and first-time use on a living person. It was flawless."

"Observing the flawless execution of this surgical plan was a highlight of my career and incredibly fulfilling. Patient safety has been painstakingly considered in virtually every aspect of our system. Our goal is to have the most efficient, most accurate and safest robot in the world. I am incredibly proud of the hard work of our team and to have had the opportunity to help build this technology," said Kamran Shamaei, Chief Technical Officer.

"I feel proud to have played a part in the development of the Monogram TKA System and to have been a member of this incredible team," said Aniruddh Nayak, Sr. Manager of Clinical R&D. "As the individual responsible for the execution of this trial I feel a huge weight of responsibility. To see the system do it's job and execute the surgical plan as it did was extremely fulfilling. I believe our product will have a significant clinical impact globally."

Strategic partner Shalby Limited (NSE: SHALBY) ("Shalby"), one of the world's largest orthopedic hospital groups, will support the 102-patient clinical investigation evaluating the safety and effectiveness of the Monogram TKA System, one of the world's first saw-based autonomous robots.

"I founded Shalby Hospitals to be a world-renowned center of excellence and innovation for joint replacement surgeries," said Dr. Vikram Shah, founder of Shalby Hospitals. "My vision has always been to pioneer advanced technologies in the field of orthopedic medicine. Having performed thousands of surgeries, I was deeply impressed by what the Monogram team has accomplished and by what was achieved in this surgery, and I look forward to supporting the introduction of this state-of-the-art robotic system, which reaffirms Shalby's commitment to leading innovation and excellence in joint replacement surgeries."

The U.S. Food and Drug Administration (FDA) <u>recently granted 510(k) clearance</u> for Monogram's mBôs semi-autonomous TKA System.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. <u>recently announced</u> they entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of stock of Monogram.

**About Monogram Technologies Inc.**

Monogram Technologies (NASDAQ: MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics.

To learn more, visit <u>www.monogramtechnologies.com</u>.

**Forward-Looking Statements**

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the Company's filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

**Investor Relations**

Chris Tyson<br> Executive Vice President<br> MZ North America<br> Direct: 949-491-8235<br> <u>MGRM@mzgroup.us</u>